Usage Examples
- The distribution data for the annual report has to come out of the ERP, not the forecast deck.
- That change has minimal potential to affect quality, so it goes in the AR rather than a supplement.
- We missed the approval anniversary by nine days, so the AR went in late.
What is Annual Report (AR)?
Annual Reports are the yearly postmarketing filing required for every approved NDA, ANDA, and BLA, covering distribution, labeling, and minor manufacturing changes that do not rise to the level requiring a supplement.
Annual Reports exist because FDA's oversight of a product does not stop at approval, and most postapproval change is too small to justify a supplement. Rather than let years of minor edits to labeling, suppliers, specifications, and distribution accumulate unseen, the regulation forces the applicant to put them on the record once a year, on a clock the agency sets.
Annual Reports cover distribution volumes, current labeling, minor chemistry and manufacturing changes, new nonclinical and clinical findings, and the status of every postmarketing study commitment. They do not cover anything with more than minimal potential to affect identity, strength, quality, purity, or potency. Those changes need a prior approval supplement or a changes-being-effected filing instead, before or as the change is made.
Annual Reports run on the approval anniversary, not the company's fiscal year, so a portfolio of twenty products carries twenty separate due dates. Each report is assembled from CMC change logs, labeling history, distribution figures, and study status that sit in four different systems, then filed with a completed Form FDA 2252. Misreading the clock or omitting a committed study is the usual failure.
Not to be confused with
- Prior Approval Supplement
- a PAS must be reviewed and approved by FDA before the change is implemented. The annual report is filed after the change is already in place, and only for changes with minimal potential to affect product quality.
- PADER
- the periodic adverse drug experience report under 21 CFR 314.80(c)(2) carries safety cases, not manufacturing or distribution content. It runs quarterly for the first three years after approval and annually after that, so early in a product's life the two reports are on different clocks.
- IND annual report
- filed against the anniversary of the date the IND went into effect, for a drug still in development, under 21 CFR 312.33. Different trigger, different content, and it continues for as long as the IND is open.
- Corporate or SEC annual report
- a financial disclosure to shareholders. Identical name, unrelated obligation; the two collide constantly in search and in document management systems.
Obligations differ by application type, and the clock is set by the approval date rather than the calendar.
What you must do
- 1Submit the report within 60 days of the anniversary date of U.S. approval, in two copies, accompanied by a completed transmittal Form FDA 225221 CFR 314.81(b)(2)
- 2Report the quantity of drug product distributed under the approved application, including quantities distributed to distributors21 CFR 314.81(b)(2)(ii)
- 3Include a status report for each postmarketing study FDA required or the applicant committed to in writing, spanning clinical safety, clinical efficacy, clinical pharmacology, and nonclinical toxicology21 CFR 314.81(b)(2)(vii)
- 4For a licensed biologic, document in the annual report each change with minimal potential to adversely affect identity, strength, quality, purity, or potency, naming the sites involved, the date the change was made, and the relevant validation cross-references21 CFR 601.12(d)
- 5For a drug still under an open IND, file a separate annual report within 60 days of the anniversary of the date the IND went into effect, summarizing the status of each study21 CFR 312.33
Common mistakes
Running the report on the fiscal year instead of the approval anniversary
the due date is 60 days after the anniversary of U.S. approval of that specific application. Teams that batch every product into one internal cycle file late on most of them, and lateness sits permanently in the application file for any reviewer to find.
Downgrading a supplement-level change into the annual report
if a change has more than minimal potential to affect identity, strength, quality, purity, or potency, reporting it annually means product was distributed under a change FDA never approved. The correction is a retroactive supplement plus a decision about material already in the market.
Filing the CMC and distribution sections but skipping postmarketing commitment status
the status report on each required or committed study is an explicit line item, and it is the one most often dropped because it lives with clinical operations rather than regulatory. Omission draws an information request and pulls review attention back onto the whole file.
When This Matters
- The distribution data for the annual report has to come out of the ERP, not the forecast deck.
- That change has minimal potential to affect quality, so it goes in the AR rather than a supplement.
- We missed the approval anniversary by nine days, so the AR went in late.
Frequently Asked Questions
Within 60 days of the anniversary date of U.S. approval of the application. The clock runs off the approval date of that specific NDA, ANDA, or BLA, not the company's fiscal year, so each product in a portfolio carries its own due date. Two copies are required, with transmittal Form FDA 2252.
Related Use Cases
- Pharma Use Cases
Cut NDA and sNDA prep time by 60% with AI-assisted drafting and automated readiness checks
- Biotech Use Cases
Compress IND prep from 8-12 weeks to under 3 weeks with AI-assisted drafting and validation
- Regulatory Affairs Workflows
Cut regulatory intelligence tracking from 10+ hours/week to automated, real-time alerts
- CMC Workflows
Track ICH quality guidelines automatically and get alerts when changes impact your products
